Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01296191 · ClinicalTrials.gov registry record · Phase 4
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
A Phase 4 study of Cataracts, sponsored by Frank A. Bucci, Jr., M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT01296191: Completed Phase 4 study of Cataracts, sponsored by Frank A. Bucci, Jr., M.D..
NCT01296191 is a Phase 4 study of Cataracts that has completed, run by Frank A. Bucci, Jr., M.D.. The registered enrollment target is 120 participants, above the 83-participant average among 8 other Cataracts trials with a reported enrollment target (45% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01296191, a Phase 4 study of Cataracts, has completed, sponsored by Frank A. Bucci, Jr., M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare drug concentrations in aqueous humor following ocular instillation of Besivance and VIGAMOX in subjects undergoing cataract surgery.
Primary Outcome
Concentration of Besivance and VIGAMOX in the aqueous humor will be determined by an independent laboratory using standardized high-pressure liquid chromatography and mass spectrometry assays. Pharmacokinetic parameters determined from the aqueous humor concentration will minimally include the area under the curve and the maximum concentration.
Conditions Studied
Interventions
- DRUG Moxifloxacin
- DRUG besifloxacin
Study Locations (1)
Pennsylvania
- Bucci Laser Vision Institute - Wilkes-Barre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
What the finished NCT01296191 record still lists
NCT01296191 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 83-participant average among 8 other Cataracts trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Cataracts appearing as the primary indexed condition, and to 2 interventions - of which Moxifloxacin is the first listed.
NCT01296191 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01296191 about?
NCT01296191 is a clinical study titled "Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification". The purpose of this study is to compare drug concentrations in aqueous humor following ocular instillation of Besivance and VIGAMOX in subjects undergoing cataract surgery.
What is the current status of trial NCT01296191?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2011-05. Estimated completion is 2013-01.
What conditions does trial NCT01296191 study?
This clinical trial studies the following conditions: Cataracts.
What interventions are being tested in trial NCT01296191?
The interventions under investigation include: Moxifloxacin (DRUG), besifloxacin (DRUG).
Who is sponsoring clinical trial NCT01296191?
This trial is sponsored by Frank A. Bucci, Jr., M.D., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01296191 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataracts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01296191's enrollment target sits among peer trials
120 3rd of 8 higher than 6 of 8 other Cataracts trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataracts trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
COMPLETED · Phase 4
-
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
COMPLETED · Phase 4
-
Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery
COMPLETED · Phase 4
-
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
COMPLETED · Phase 4
-
Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia